Related references
Note: Only part of the references are listed.Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update
Nasreen Alsayed et al.
ATHEROSCLEROSIS (2022)
Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
Ahmed Alghamdi et al.
PHARMACOECONOMICS-OPEN (2022)
The Impact of the Coronavirus Disease 2019 Pandemic on Adherence to Ocular Hypotensive Medication in Patients with Primary Open-Angle Glaucoma
Lyne Racette et al.
OPHTHALMOLOGY (2022)
Patient satisfaction with pharmaceutical care services for chronic diseases and their medication adherence during COVID-19 in Saudi Arabia
Jisha M. Lucca et al.
INTERNATIONAL JOURNAL OF PHARMACY PRACTICE (2022)
Knowledge, attitudes, and impact of COVID-19 pandemic among neurology patients in Jordan: a cross-sectional study
Mohammad Athamneh et al.
EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY (2021)
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies
Martha L. Daviglus et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome
Bradley Sarak et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)
Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
Konstantinos Tsioufis et al.
CARDIOLOGY AND THERAPY (2021)
Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry
Khalid F. Alhabib et al.
PLOS ONE (2021)
The impact of COVID-19 on self-management behaviours and healthcare access for people with inflammatory arthritis
Emma Caton et al.
BMC RHEUMATOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials
Guangyan Mu et al.
ADVANCES IN THERAPY (2020)
LDL-C: lower is better for longer-even at low risk
Peter E. Penson et al.
BMC MEDICINE (2020)
Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries
Nelly Ziade et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 Update From the GBD 2019 Study
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort
Martin Bodtker Mortensen et al.
LANCET (2020)
Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan
Mayumi Wake et al.
ATHEROSCLEROSIS (2019)
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis
Zonglei Zhao et al.
MEDICINE (2019)
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden
Karam Turk-Adawi et al.
NATURE REVIEWS CARDIOLOGY (2018)
A systematic literature review comparing methods for the measurement of patient persistence and adherence
Carol A. Forbes et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results From the Cooper Center Longitudinal Study
Shuaib M. Abdullah et al.
CIRCULATION (2018)
Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
Jennifer G. Robinson et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries
Lisandro D. Colantonio et al.
JAMA CARDIOLOGY (2017)
Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care
Valeria Guglielmi et al.
ATHEROSCLEROSIS (2017)
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)
Chern-En Chiang et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf
Khalid Al-Rasadi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment
Saud N. Al Sifri et al.
PLOS ONE (2014)
Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients
Sayed H. Naderi et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Share Paper
